Completed PHASE2/PHASE3 INTERVENTIONAL NCT00319033

Open-label Study With Bosentan in Interstitial Lung Disease (BUILD 2 OL)

Long-term Open-label Study in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Who Completed the Protocol AC-052-330.

Sponsor: Actelion

Conditions Interstitial Lung Disease Scleroderma

Interventions bosentan

Updated 7 times since 2017 Last updated: Jan 31, 2025 Started: Jul 31, 2004 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Interstitial Lung Disease and Scleroderma, this trial is completed. The trial is conducted by Actelion and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Mar 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actelion

Data source: Actelion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.